Clinical bottom line
High-intensity focused ultrasound (HIFU) is an emerging noninvasive modality showing promise for pain management in osteoarthritis (OA), particularly for patients with refractory symptoms who are poor candidates for surgery or systemic analgesics. While robust data specific to OA remain limited, early clinical evidence and mechanistic rationale support HIFU’s potential to reduce pain by targeted ablation of periarticular nerve fibers and modulation of local inflammatory processes. However, definitive efficacy, optimal treatment protocols, and long-term safety require further validation in well-designed trials before routine implementation in orthopedic practice.
What the evidence shows
HIFU delivers focused acoustic energy to precise tissue targets, generating localized thermal and mechanical effects that can ablate nerve fibers or alter nociceptive signaling pathways (AccessScience, DOI:10.1036/1097-8542.yb031005). Its analgesic utility has been most extensively studied in cancer-related pain syndromes, where it has demonstrated significant pain reduction and opioid-sparing effects (Brown et al., 2022; Liu et al., 2025). These findings provide a mechanistic and clinical foundation for exploring HIFU in chronic musculoskeletal pain conditions such as OA.
Although direct evidence in OA is sparse, analogous applications of HIFU in pain management suggest potential benefits. For example, deSouza et al. (2015) reviewed magnetic resonance-guided HIFU for cancer pain, highlighting precise targeting and minimal invasiveness, features desirable in OA treatment to minimize joint damage. Additionally, low-intensity focused ultrasound (LIFU) has been investigated for neuromodulation and analgesia in various pain states, indicating that ultrasound parameters can be tuned for therapeutic effects without tissue destruction (legon et al., 2024).
HIFU’s mechanism in OA pain likely involves ablation or modulation of periarticular sensory nerves and reduction of local inflammatory mediators, which are key contributors to OA pain pathophysiology. Saedi et al. (2015) described HIFU’s ability to induce localized tissue changes noninvasively, supporting its use in targeting pain generators without systemic side effects.
Caveats and uncertainty
The current evidence base for HIFU in OA pain management is largely extrapolated from cancer pain and experimental neuromodulation studies rather than direct clinical trials in OA populations. There is a lack of randomized controlled trials assessing efficacy, optimal dosing, treatment intervals, and long-term outcomes in OA patients. Safety data specific to joint applications are also limited, raising concerns about potential collateral tissue damage, joint function impairment, or unintended nerve injury.
Moreover, variability in HIFU devices, guidance modalities (ultrasound vs. MRI), and treatment protocols complicates generalizability. The heterogeneity of OA phenotypes and pain mechanisms further challenges patient selection and prediction of responders. The cost, availability, and need for specialized equipment and training may limit widespread adoption in routine orthopedic practice at present.
How this may change practice
If ongoing and future studies validate HIFU’s efficacy and safety in OA pain, it could become a valuable adjunct or alternative to pharmacologic and surgical interventions, especially for patients with contraindications to systemic analgesics or who seek noninvasive options. HIFU might be integrated into multimodal pain management pathways, potentially reducing opioid reliance and improving quality of life.
Orthopedic clinicians should remain informed about emerging evidence and evolving guidelines regarding HIFU. Collaboration with pain specialists and radiologists experienced in focused ultrasound may facilitate patient selection and procedural planning. Until high-quality OA-specific data are available, HIFU should be considered experimental and offered within clinical trials or specialized centers.